Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.68
+0.11 (1.97%)
At close: Feb 21, 2025, 4:00 PM
5.70
+0.02 (0.35%)
After-hours: Feb 21, 2025, 5:01 PM EST
Verastem Revenue
Verastem had revenue of $10.00M in the twelve months ending September 30, 2024.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
17.17
Revenue / Employee
$136,986
Employees
73
Market Cap
260.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
VSTM News
- 1 day ago - Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - Business Wire
- 24 days ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire
- 4 weeks ago - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 5 weeks ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 5 weeks ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 5 weeks ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 6 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha